# Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)

> **NCT07573436** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Utah** · enrollment: 23 (estimated)

## Conditions studied

- Post-transplant Lymphoproliferative Disorder

## Interventions

- **DRUG:** Loncastuximab tesirine
- **DRUG:** Rituximab or rituximab biosimilar

## Key facts

- **NCT ID:** NCT07573436
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2030-06
- **Final completion:** 2031-06
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07573436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07573436, "Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07573436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*